Free shipping on all orders over $ 500

Naporafenib

Cat. No. M10152
Naporafenib Structure
Synonym:

LXH254

Size Price Availability Quantity
5mg USD 140  USD140 In stock
10mg USD 220  USD220 In stock
25mg USD 440  USD440 In stock
50mg USD 680  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Naporafenib (also known as LXH254) is an orally available inhibitor of C-Raf and B-Raf with potential antineoplastic activity. Naporafenib (LXH254) has demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. Moreover, LXH254 is a Type 2 ATP -competitive inhibitor of both B-Raf and C-Raf that keeps the kinase pocket in an inactive conformation, thereby reducing the paradoxical activation seen with many B-Raf inhibitors, and blocking mutant RAS-driven signaling and cell proliferation.

Naporafenib (LXH254) exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes. Treatment with Naporafenib (LXH254) generates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C).

Chemical Information
Molecular Weight 502.49
Formula C25H25F3N4O4
CAS Number 1800398-38-2
Solubility (25°C) DMSO ≥ 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kelli-Ann Monaco, et al. Clin Cancer Res. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

[2] Siyeon Park, et al. Cancer Lett. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells

[3] Marcelo V Negrao, et al. J Thorac Oncol. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

[4] Shubham Atal, et al. J Clin Pharm Ther. Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update

Related Raf Products
Cyclorasin 9A5

Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM.

R18

R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM.

PROTAC RAF degrader 1

PROTAC RAF degrader 1 is a PROTAC RAF degrader.

B-Raf IN 15

B-Raf IN 15 is a BRAF inhibitor.

Raf inhibitor 3

Raf inhibitor 3 is a Raf inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Naporafenib, LXH254 supplier, Raf, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.